OTCMKTS:TBGNF Oxurion (TBGNF) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free TBGNF Stock Alerts $0.17 0.00 (0.00%) (As of 09/19/2023) Add Compare Share Share Today's Range$0.17▼$0.1750-Day Range$0.17▼$0.1752-Week Range$0.17▼$0.29VolumeN/AAverage Volume440 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Oxurion alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Oxurion Stock (OTCMKTS:TBGNF)Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME. Oxurion NV has collaboration agreements with Bicycle Therapeutics and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.Read More TBGNF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TBGNF Stock News HeadlinesApril 10, 2024 | finanznachrichten.deOxurion NV: Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program: Eleventh tranche fully issued and paid-upApril 10, 2024 | markets.businessinsider.comOxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-upApril 23, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 5, 2024 | finanznachrichten.deOxurion NV: Postponement Annual Shareholders Meeting - Amendment financial calendarMarch 27, 2024 | finanznachrichten.deOxurion NV: Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended versionMarch 5, 2024 | finance.yahoo.comOxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-upJanuary 22, 2024 | finanznachrichten.deOxurion NV: Oxurion Announces New Strategic Orientation to De-risk and DiversifyDecember 28, 2023 | finance.yahoo.comOxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor AtlasApril 23, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.November 20, 2023 | uk.finance.yahoo.comOxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular EdemaNovember 14, 2023 | morningstar.comOxurion NV OXUROctober 1, 2023 | uk.finance.yahoo.comOxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023September 29, 2023 | uk.finance.yahoo.comOxurion Publishes First Half 2023 ResultsSeptember 19, 2023 | finance.yahoo.comOxurion Receives First EUR 1 Million under Amended Atlas Funding ProgramAugust 11, 2023 | msn.comOxurion unlocks $1m from Atlas for diabetic macular oedema therapyAugust 11, 2023 | finanznachrichten.deOxurion NV: Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding ProgramAugust 8, 2023 | uk.finance.yahoo.comOxurion NV (TG4.BE)July 27, 2023 | finanznachrichten.deOxurion NV: Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLJuly 27, 2023 | finance.yahoo.comOxurion Receives Transparency Notifications from Atlas Special Opportunities LLJuly 25, 2023 | finanznachrichten.deOxurion NV: Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIBJuly 25, 2023 | finance.yahoo.comOxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIBJune 15, 2023 | finance.yahoo.comOxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLCJune 1, 2023 | finance.yahoo.comOxurion to Participate in Upcoming ConferencesMay 25, 2023 | finanznachrichten.deOxurion NV: Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular EdemaMay 22, 2023 | finance.yahoo.comOxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLCApril 27, 2023 | finanznachrichten.deOxurion NV: Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLCApril 27, 2023 | finance.yahoo.comOxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLCSee More Headlines Receive TBGNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxurion and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:TBGNF CUSIPN/A CIKN/A Webwww.oxurion.com Phone(321) 675-1317FaxN/AEmployees27Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Thomas Graney C.F.A. (Age 58)CEO, CFO & Director Comp: $598.7kMr. Wouter PiepersGlobal Head of Corp. Communications & Investor RelationsMs. Kathleen PaisleyChief Legal Officer & Compliance OfficerDr. Andy De Deene M.B.A.M.D., Chief Devel. OfficerMr. Michael DillenChief Bus. Officer & Company Sec.Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors TBGNF Stock Analysis - Frequently Asked Questions How have TBGNF shares performed in 2024? Oxurion's stock was trading at $0.17 at the start of the year. Since then, TBGNF stock has increased by 0.0% and is now trading at $0.17. View the best growth stocks for 2024 here. How do I buy shares of Oxurion? Shares of TBGNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:TBGNF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxurion NV Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
